All News
Provan et al. large scandinavian registry study: š«ILD risk in RA & PsA initiating b/tsDMARDs
HR ILD RA=10
HR ILD PsA=5
No increase risk w/ MTX and b/tsDMARDs but RA HR ILD 1.7 RTX vs. ETA: confounding by indication?
https://t.co/CF1ysNkQxU OP0006 #EULAR23 @Rheumnow https://t.co/DgDE1uFeUs
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 #OP0051 4-year Pooled Analyses of 3 x Anifrolumab RCTs in #lupus (inc. LTE) showed:
- LLDAS was attained earlier & more cumulative time was spent in LLDAS in anifrolumab compared to placebo groups
Assuring longer-term data
*sorry photos werenāt permitted @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but thatās now 10% of the population, & many patients have more than one. Most are lifelong.
Surely this needs more investment??
CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq
David Liew drdavidliew ( View Tweet)
https://t.co/0FsCCOP17E OP0044 #EULAR23 @RheumNow https://t.co/pl0AnGUAw1
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Scandinavian RA registry study shows reassuring data on CV risk in RAš«
Acute Coronary Syndrom incidence rates are similar in RA pts achieving remission & general pop & is similar whether RA pts reach remission using MTX or TNFi.
https://t.co/wBDZtaTVba
OP0038 #EULAR23 @Rheumnow https://t.co/JLdbYF49xF
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Data from combined big Scandinavian population registries looking at both RA and PsA, ILD development, & MTX exposure
Hereās the ILD risk for methotrexate.
Can we stop this MTX misinformation? No more besmirching a really useful drug for our patients #EULAR2023 OP0006 @RheumNow https://t.co/7swqAYchDC
David Liew drdavidliew ( View Tweet)
Interstitial lung disease in RA and PSA in b/tsDMARD treated patients with MTX - there is no increased risk of developing ILD above the background risk of RA and PsA vs general population Sella Aarrestad Provan Abst#OP0006 @RheumNow https://t.co/yJsrmraeZ5
Dr. Antoni Chan synovialjoints ( View Tweet)
Comorbidities and metabolic burden in PsA:
-Occur EARLY
-Early PsA pts > multiple comorbidities & > CV morbidity vs. age-matched early RA pts
Independent of BMI & obesity
Time to address these as part of dis pathogenesis in PsA
https://t.co/qOiGHn2eZT OP0066 #EULAR23 @Rheumnow https://t.co/lK7MbeMybO
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
AxSpA can be unequivocally diagnosed in the first 2 years of onset of chronic back pain with 30% definite with HLA-B27+ and imaging being the key SpA features from the SPACE cohort by
Mary Lucy Marques, Abst #OP0005 @RheumNow https://t.co/m5umD00hDf
Dr. Antoni Chan synovialjoints ( View Tweet)
With all the benefits of MRI and expert rheumatologists, do our diagnoses of axSpA stick, two years later?
Overwhelmingly yes, but sometimes we do actually have to change our minds. Beware the set and forget for our clinical diagnoses
SPACE cohort #EULAR2023 OP0005 @RheumNow https://t.co/AN6XzqKlv3
David Liew drdavidliew ( View Tweet)
New benefit/risk outlook š on ORAL surveillance
2 subgrps:
š¢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi
AND risk of MACE is comparable šRA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE
https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2023 Abstr #OP0048 What happened if we taper steroid in #lupus patients who are Serologically Active Clinically Quiescent? A cohort study in Asia showed:
- Tapering was NOT associated with subsequent flare
- Tapering reduced damage in those on =>5mg/day
@RheumNow https://t.co/Q6GiaSCgV6
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Improving access and education to SLE patients using the Lupus 100 project which uses native language covering 95% of the European population to provide high quality and accurate information for patients by Zoe Karakla-Mitsakou Abst#OP0004 @RheumNow https://t.co/mWRiZt7uGy
Dr. Antoni Chan synovialjoints ( View Tweet)
Great patient-driven initiative to get accurate and relevant lupus information to SLE patients. Avoid misinformation and check it out in your language at https://t.co/R2ydvDasFY
Congratulations @LupusEurope!
#EULAR2023 OP0004 @RheumNow https://t.co/S4sgy5dnro
Links:
David Liew drdavidliew ( View Tweet)
Leiden arthritis clinic:
1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at dis onset but NOT synovitis
RA w/ overweight/obesity 25% < MRI-detected erosive progression at 2 yrs
More marked in ACPA+ pts
Is leptin the missing link? š¤
OP0039 #EULAR23 @Rheumnow https://t.co/RRSV9VlRtn
Aurelie Najm AurelieRheumo ( View Tweet)
Biosimilar vs originator: as switches loom in the US, once again itās really hard to say we see any differences in drug survival for our RA patients
These data from forced switching in BC, Canada are just like the others - biosimilars are business as usual. POS0567 #EULAR2023 https://t.co/Ebl1hTM4qE
David Liew drdavidliew ( View Tweet)
Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step to study the etiology of immune changes from these life prolonging medications #EULAR2023 @RheumNow https://t.co/Bv1q8IphqF
Janet Pope Janetbirdope ( View Tweet)
Different B cell depleting agents! #Eular2023 https://t.co/GsmdIHgOcl
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Can #machine #learning replace #rheumatologists? OP0190 #EULAR23 #Machine learning can help determine who will develop #rheumatoidarthritis in Pts with #arthralgia but the real study could be ask #clinician the #probability of RA and do #AI and see comparative accuracy @RheumNow
Janet Pope Janetbirdope ( View Tweet)
There are lots of reasons why axSpA treatments fail for patients. And as rheumatologists, we canāt just prescribe and walk away - we need to address each in turn, for our patientsā sake #EULAR2023 @RheumNow https://t.co/hzo57BaEXw
David Liew drdavidliew ( View Tweet)